Lispro胰島素市場：依產品類型、適應症、年齡層、藥物類別、通路Lispro地區分類

Insulin Lispro Market, By Product Type of Insulin Lispro, By Indication, By Age Group, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年Lispro胰島素市場規模將達87.8億美元，預計2033年將達到135.5億美元。預計2026年至2033年，其複合年成長率將達6.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	87.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.40%	2033年市場規模預測：	135.5億美元

Lispro胰島素用於治療需要胰島素治療的第一型糖尿病（一種人體無法產生胰島素且血糖值無法控制的疾病）。除與外置胰島素幫浦合併使用外，賴脯胰島素通常與其他類型的胰島素合併使用。對於單獨使用口服胰島素療效不佳的第二型糖尿病成人患者，也可使用Lispro胰島素注射改善血糖控制。Lispro脯胰島素是一種胰島素類似物，其特徵是與人類胰島素相比，賴脯胰島素在兩個胺基酸序列上有差異：B-28位為脯胺酸，B-29位為離胺酸。這種差異可防止胰島素形成二聚體或六聚體。二聚體和六聚體的活性低於單體胰島素。皮下注射後，Lispro胰島素迅速吸收，2-4小時內達到血中濃度峰值，藥效持續18-30小時。

市場動態：

近年來，全球Lispro胰島素市場顯著成長，主要原因是糖尿病患者人數不斷增加以及胰島素輸注裝置的技術進步。預計已開發國家政府加大力度改善醫療保健、患者對胰島素的需求不斷成長以及有利的醫療報銷政策等因素將進一步推動這一成長。久坐不動的生活方式和不健康的飲食習慣等生活方式的改變，是導致全球糖尿病患者人數增加的主要原因。根據國際糖尿病聯盟（IDF）的數據，2021年全球約有5.37億成年人患有糖尿病，預計到2030年這一數字將增加至6.43億，到2045年將達到7.84億。肥胖率上升和久坐不動的生活方式是導致糖尿病患者人數增加的主要因素。然而，胰島素類似物的高成本和生物相似藥的激增仍然是市場成長面臨的挑戰。另一方面，開發中國家政府的積極努力和醫療服務可近性的改善，為在該市場運營的公司提供了廣泛的機會。此外，胰島素類似物給藥裝置和製劑的研發很可能成為影響未來市場趨勢的因素。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球胰島素Lispro市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份全球賴Lispro市場報告旨在為產業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球賴Lispro胰島素市場中使用的各種策略矩陣來簡化決策過程。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 8.78 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.40%	2033 Value Projection:	USD 13.55 Bn

Insulin lispro is used to treat type 1 diabetes (a condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used with an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remaining effective for 18-30 hours.

Market Dynamics:

The global insulin lispro market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries. Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. As per the International Diabetes Federation, approximately 537 Mn adults were living with diabetes in 2021, and this number is expected to rise to 643 Mn by 2030 and 784 Mn by 2045. The increasing obesity rates and sedentary lifestyles have significantly contributed to this rise in diabetes cases. However, the high costs of insulin analogs and the availability of biosimilar alternatives remain a challenge for market growth. On the positive side, favorable government initiatives and improved access to healthcare services in developing nations present lucrative opportunities for players operating in this market. Developments in analog insulin delivery devices and formulations will also likely shape the future dynamics.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global insulin lispro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Insulin Lispro Market Detailed Segmentation:

By Product Type (Revenue, USD Bn, 2021 - 2033)
Insulin Lispro pre-filled pen
Insulin lispro solution vials
Insulin lispro solution cartridge
By Indication (Revenue, USD Bn, 2021 - 2033)
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Others
By Age Group (Revenue, USD Bn, 2021 - 2033)
Pediatric Patients
Adult Patients
Geriatric Patients
By Drug Class (Revenue, USD Bn, 2021 - 2033)
Humalog (Eli Lilly and Company)
Admelog (Sanofi)
Other brands
By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Eli Lilly and Company
Sanofi
Novo Nordisk A/S
Merck & Co., Inc.
Pfizer Inc.
Hoffmann-La Roche Ltd.
AstraZeneca PLC
Johnson & Johnson Services, Inc.
Biocon Limited
Mylan N.V.
Boehringer Ingelheim International GmbH
Wockhardt Ltd.
Lupin Pharmaceuticals, Inc.
Bioton S.A.
Gan & Lee Pharmaceuticals
Ypsomed AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Insulin Lispro, By Product Type of Insulin Lispro
- Market Insulin Lispro, By Indication
- Market Insulin Lispro, By Age Group
- Market Insulin Lispro, By Drug Class
- Market Insulin Lispro, By Distribution Channel
- Market Insulin Lispro, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Growing prevalence of diabetes
- Restrains
- Opportunities
  - Growing launch of new product
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER€(TM)s Analysis
Merger and Acquisition Scenario

4. Insulin Lispro Market , By Product Type of Insulin Lispro, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
Insulin Lispro pre-filled pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Insulin lispro solution vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Insulin lispro solution cartridge
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

5. Insulin Lispro Market , By Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Insulin Lispro Market , By Age Group, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
Paediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

7. Insulin Lispro Market , By Drug Class, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
Humalog (Eli Lilly and Company)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Admelog (Sanofi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Other Brands
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

8. Insulin Lispro Market , By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

9. Insulin Lispro Market , By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2026 €"2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033,(US$ Bn)

10. Competitive Landscape

Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Biocon Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Wockhardt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lupin Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bioton S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gan & Lee Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Ypsomed AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views